Abstract
Specific allergen immunotherapy (SIT) is the only disease-modifying treatment for allergic rhinitis and asthma. Subcutaneous immunotherapy (SCIT) is the only method with a US Food and Drug Administration (FDA)-approved formulation, but safety concerns limit administration to medical facilities. Sublingual immunotherapy (SLIT), under investigation in the United States, appears to have a more favorable safety profile, which may expand its use to populations generally not treated with SIT (eg, young children). This paper reviews SLIT studies that were specifically limited to the pediatric population. Most demonstrated evidence of clinical efficacy, but approximately 29% failed to demonstrate efficacy in symptom and medication scores in the first treatment year. Efficacy was seen in a broad range of allergen doses, but optimal dose range has not been established. SLIT appeared to be well tolerated in children as young as 2 years, but serious adverse reactions, including anaphylaxis, were reported. SLIT is a promising immunotherapy that may expand the population receiving SIT because of the convenience of home administration due to its favorable safety profile. However, questions remain unanswered, including optimal therapeutic dose.
Similar content being viewed by others
References and Recommended Reading
Durham SR, Walker SM, Varga EM, et al.: Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999, 341:468–475.
The Childhood Asthma Management Program Research Group: Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000, 343:1054–1063.
Guilbert TW, Morgan WJ, Zeiger RS, et al.: Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006, 354:1985–1997.
Ariano R, Berto P, Tracci D, et al.: Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma. Allergy Asthma Proc 2006, 27:159–163.
Eng PA, Borer-Reinhold M, Heijnen IAFM, Gnehm HPE: Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 2006, 61:198–201.
Moller C, Dreborg S, Ferdousi HA, et al.: Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002, 109:251–256.
Niggemann B, Jacobsen L, Dreborg S, et al.: Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy 2006, 61:855–859.
Des Roches A, Paradis L, Menardo JL, et al.: Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997, 99:450–453.
Pajno GB, Barberio G, De Luca F, et al.: Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001, 31:1392–1397.
Greisner WA 3rd, Settipane RJ, Settipane GA: Natural history of hay fever: a 23-year follow-up of college students. Allergy Asthma Proc 1998, 19:271–275.
Hankin CS, Cox L, Wang Z, Bronstone A: Allergy immunotherapy practice patterns and associated outcomes of care [abstract]. J Allergy Clin Immunol 2007, 119:S344.
Bernstein JA: Pharmacoeconomic considerations for allergen immunotherapy. Clin Allergy Immunol 2004, 18:151–164.
Subcutaneous immunotherapy. Allergy 2006, 61(Suppl 82):5–13.
Cox L, Li J, Nelson H, Lockey R: Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol 2007, 120:S25–S85.
Di Rienzo V, Pagani A, Parmiani S, et al.: Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients. Allergy 1999, 54:1110–1113.
Lombardi C, Gargioni S, Melchiorre A, et al.: Safety of sublingual immunotherapy with monomeric allergoid in adults: multicenter post-marketing surveillance study. Allergy 2001, 56:989–992.
Cox LS, Linnemann DL, Nolte H, et al.: Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006, 117:1021–1035.
Jacobsen L, Niggemann B, Dreborg S, et al.: Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007, 62:943–948.
Caffarelli C, Sensi LG, Marcucci F, Cavagni G: Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial. Allergy 2000, 55:1142–1147.
Pajno GB, Vita D, Parmiani S, et al.: Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate. Clin Exp Allergy 2003, 33:1641–1647.
Rolinck-Werninghaus C, Wolf H, Liebke C, et al.: A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen. Allergy 2004, 59:1285–1293.
Wuthrich B, Bucher C, Jorg W, et al.: Double-blind, placebo-controlled study with sublingual immunotherapy in children with seasonal allergic rhinitis to grass pollen. J Investig Allergol Clin Immunol 2003, 13:145–8.
Yuksel H, Tanac R, Gousseinov A, Demir E: Sublingual immunotherapy and influence on urinary leukotrienes in seasonal pediatric allergy. J Investig Allergol Clin Immunol 1999, 9:305–313.
Lue KH, Lin YH, Sun HL, et al.: Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol 2006, 17:408–415.
Niu CK, Chen WY, Huang JL, et al.: Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: A multi-center, double-blind, randomized, and placebo-controlled study in Taiwan. Respir Med 2006, 100:1374–1383.
Savolainen J, Jacobsen L, Valovirta E: Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy 2006, 61:1184–1190.
Valovirta E, Jacobsen L, Ljorring C, et al.: Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy 2006, 61:1177–1183.
Bufe A, Ziegler-Kirbach E, Stoeckmann E, et al.: Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Allergy 2004, 59:498–504.
Hirsch T, Sahn M, Leupold W: Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children. Pediatr Allergy Immunol 1997, 8:21–27.
Ippoliti F, De Santis W, Volterrani A, et al.: Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 2003, 14:216–221.
La Rosa M, Ranno C, Andre C, et al.: Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999, 104:425–432.
Marcucci F, Sensi L, Di Cara G, et al.: Dose dependence of immunological response to sublingual immunotherapy. Allergy 2005, 60:952–956.
Novembre E, Galli E, Landi F, et al.: Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004, 114:851–857.
Pajno GB, Morabito L, Barberio G, Parmiani S: Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy, 2000:842–849.
Vourdas D, Syrigou E, Potamianou P, et al.: Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 1998, 53:662–672.
Bahceciler NN, Isik U, Barlan IB, Basaran MM: Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 2001, 32:49–55.
Tari MG, Mancino M, Monti G: Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol (Madr) 1990, 18:277–284.
Roder E, Berger MY, Hop WC, et al.: Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care. J Allergy Clin Immunol 2007, 119:892–898.
Ippoliti F, De Santis W, Volterrani A, et al.: Psychological stress affects response to sublingual immunotherapy in asthmatic children allergic to house dust mite. Pediatr Allergy Immunol 2006, 17:337–345.
Arikan C, Bahceciler NN, Deniz G, et al.: Bacillus Calmette-Guerin-induced interleukin-12 did not additionally improve clinical and immunologic parameters in asthmatic children treated with sublingual immunotherapy. Clin Exp Allergy 2004, 34:398–405.
Bahceciler NN, Arikan C, Taylor A, et al.: Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol 2005, 136:287–294.
Di Rienzo V, Marcucci F, Puccinelli P, et al.: Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 2003, 33:206–210.
Frew AJ, Powell RJ, Corrigan CJ, Durham SR: Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006, 117:319–325.
Horst M, Hejjaoui A, Horst V, et al.: Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol 1990, 85:460–472.
Kohno Y, Minoguchi K, Oda N, et al.: Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma. J Allergy Clin Immunol 1998, 102:927–934.
Varney VA, Gaga M, Frew AJ, et al.: Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. Bmj 1991, 302:265–269.
Lent AM, Harbeck R, Strand M, et al.: Immunological response to administration of standardized dog allergen extract at differing doses. J Allergy Clin Immunol 2006, 118:1249–1256.
Nanda A, O’Connor M, Anand M, et al.: Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J Allergy Clin Immunol 2004, 114:1339–1344.
Ewbank PA, Murray J, Sanders K, et al.: A double-blind placebo-controlled immunotherapy dose-response study with standardized cat extract. J Allergy Clin Immunol 2003, 111:155–161.
Creticos PS, Adkinson NF Jr, Kagey-Sobotka A, et al.: Nasal challenge with ragweed pollen in hay fever patients: effect of immunotherapy. J Clin Invest 1985, 76:2247–2253.
Haugaard L, Dahl R, Jacobsen L: A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993, 91:709–722.
Bousquet J, Hejjaoui A, Soussana M, Michel FB: Double-blind placebo-controlled immunotherapy grass-pollen allergoids. IV. Comparison of the safety and efficacy of two doses of a high-molecular-weight allergoid. J Allergy Clin Immunol 1990, 85:490–497.
Frew AJ, Powell RJ, Corrigan CJ, et al.: Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006, 117:319–325.
Durham SR, Yang WH, Pedersen MR, et al.: Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006, 117:802–809.
Purello-D’Ambrosio F, Gangemi S, Merendino RA, et al.: Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy 2001, 31:1295–1302.
Polosa R, Al-Delaimy WK, Russo C, et al.: Greater risk of incident asthma cases in adults with allergic rhinitis and effect of allergen immunotherapy: a retrospective cohort study. Respir Res 2005 6:153.
Polosa R, Li Gotti F, Mangano G, et al.: Effect of immunotherapy on asthma progression, BHR and sputum eosinophils in allergic rhinitis. Allergy 2004, 59:1224–1228.
Stewart GE 2nd, Lockey RF: Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 1992, 90:567–578.
Tripodi S, Di Rienzo Businco A, Benincori N, et al.: Safety and tolerability of ultra-rush induction, less than one hour, of sublingual immunotherapy in children. Int Arch Allergy Immunol 2006, 139:149–152.
Kleine-Tebbe J, Ribel M, Herold DA: Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy 2006, 61:181–184.
Antico A, Pagani M, Crema A: Anaphylaxis by latex sublingual immunotherapy. Allergy 2006, 61:1236–1237.
Eifan AO, Keles S, Bahceciler NN, Barlan IB: Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy 2007, 62:567–568.
Agostinis F, Tellarini L, Canonica GW, et al.: Safety of sublingual immunotherapy with a monomeric allergoid in very young children. Allergy 2005, 60:133.
Fiocchi A, Pajno G, La Grutta S, et al.: Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. Ann Allergy Asthma Immunol 2005, 95:254–258.
Rienzo VD, Minelli M, Musarra A, et al.: Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy 2005, 35:560–564.
Berto P, Bassi M, Incorvaia C, et al.: Cost effectiveness of sublingual immunotherapy in children with allergic rhinitis and asthma. Allerg Immunol (Paris) 2005, 37:303–308.
Berto P, Passalacqua G, Crimi N, et al.: Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study. Ann Allergy Asthma Immunol 2006, 97:615–621.
Lombardi C, Gani F, Landi M, et al.: Quantitative assessment of the adherence to sublingual immunotherapy. J Allergy Clin Immunol 2004, 113:1219–1220.
Marogna M, Spadolini I, Massolo A, et al.: Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more. Allergy 2004, 59:1205–1210.
Passalacqua G, Musarra A, Pecora S, et al.: Quantitative assessment of the compliance with a once-daily sublingual immunotherapy regimen in real life (EASY project: evaluation of a novel SLIT formulation during a year). J Allergy Clin Immunol 2006, 117:946–948.
Pajno GB, Vita D, Caminiti L, et al.: Children’s compliance with allergen immunotherapy according to administration routes. J Allergy Clin Immunol 2005, 116:1380–1381.
Pajno GB, Passalacqua G, Vita D, et al.: Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: a randomized controlled trial. Allergy 2004, 59883–59887.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cox, L. Sublingual immunotherapy in pediatric allergic rhinitis and asthma: Efficacy, safety, and practical considerations. Curr Allergy Asthma Rep 7, 410–420 (2007). https://doi.org/10.1007/s11882-007-0063-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11882-007-0063-6